

Special Issue

Applied Nanotechnology in Chronic Human Disease Management

Message from the Guest Editor

Nanotechnology has been known to produce significant scientific and technological advances in diverse fields, including medicine and physiology. This exciting field of research can be defined as the science and engineering involved in the design, synthesis, characterization, and application of materials and devices whose smallest functional unit is on the nanometer scale, ranging from a few to several hundred nanometers.

The aim of this Special Issue is to include original research and review manuscript describing the preparation, characterization, functionalization, and therapeutic applications in the treatment and diagnosis of chronic human diseases with the objective of improving the therapeutic outcome and quality of life of patients suffering from diseases such as:

- Heart disease
- Cancer
- Chronic lung disease
- Stroke
- Alzheimer's
- Diabetes
- Kidney disease
- Inflammatory bowel disease

Authors are invited to submit original and review articles covering all aspects of nanocarriers designed for effective drug delivery and diagnosis. Dr. Murtaza. M. Tambuwala

Guest Editor

Dr. Murtaza M. Tambuwala

School of Pharmacy and Pharmaceutical Science, Ulster University,
Coleraine BT52 1SA, UK

Deadline for manuscript submissions

closed (30 September 2021)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/45828

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, New Jersey 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).